Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells

Journal of Immunology

Volumn 171, Issue 7, 2003, Pages 3467-3474

  Rivoltini, Licia ^a   Castelli, Chiara ^a   Carrabba, Matteo ^a   Mazzaferro, Vincenzo ^a   Pilla, Lorenzo ^a   Huber, Veronica ^a   Coppa, Jorgelina ^a   Gallino, Gianfrancesco ^a   Scheibenbogen, Carmen ^b   Squarcina, Paola ^a   Cova, Agata ^a   Camerini, Roberto ^c   Lewis, Jonathan J ^d   Srivastava, Pramod K ^e   Parmiani, Giorgio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Sigma Tau SpA   (Italy)

^d Antigenics   (United States)

^e UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CD8 ANTIGEN; CELL ADHESION MOLECULE; GAMMA INTERFERON; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 96; HLA A ANTIGEN; MELAN A; MELANOMA ANTIGEN; TETRAMER; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; CELL SPECIFICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MELANOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN METABOLISM; T LYMPHOCYTE ACTIVATION; TUMOR REGRESSION; VACCINATION;

EID: 0141955112     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.171.7.3467     Document Type: Article

References (32)

1. Hartl, F. U., and M. Hayer-Hartl. 2002. Molecular chaperones in the cytosol: from nascent chain to folded protein. Science 295:1852.
2. Srivastava, P. 2002. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu. Rev. Immunol. 20:395.
3. Schild, H., D. Arnold-Schild, E. Lammert, and H. G. Rammensee. 1999. Stress proteins and immunity mediated by cytotoxic T lymphocytes. Curr. Opin. Immunol. 11:109.
4. Vabulas, R. M., S. Braedel, N. Hilf, H. Singh-Jasuja, S. Herter, P. Ahmad-Nejad, C. J. Kirschning, C. Da Costa, H. G. Rammensee, H. Wagner, and H. Schild. 2002. The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway J. Biol. Chem. 277:20847.
5. Binder, R. J., D. K. Han, and P. K. Srivastava. 2000. CD91: a receptor for heat shock protein gp96. Nat. Immun. 1:151.
6. Wearsch, P. A., and C. V. Nicchitta. 1997. Interaction of endoplasmic reticulum chaperone GRP94 with peptide substrates is adenine nucleotide- independent. J. Biol. Chem. 272:5152.
7. Linderoth, N. A., M. N. Simon, N. A. Rodionova, M. Cadene, W. R. Laws, B. T. Chait, and S. Sastry. 2001. Biophysical analysis of the endoplasmic reticulum-resident chaperone/heat shock protein HSP96/GRP94 and its complex with peptide antigen. Biochemistry 40:1483.
8. Linderoth, N. A., A. Popowicz, and S. Sastry. 2000. Identification of the peptide-binding site in the heat shock chaperone/tumor rejection antigen HSP96 (Grp94). J. Biol. Chem. 275:5472.
9. Blachere, N. E., Z. Li, R. Y. Chandawarkar, R. Suto, N. S. Jaikaria, S. Basu, H. Udono, and P. K. Srivastava. 1997. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J. Exp. Med. 186:1315.
10. Nieland, T. J., M. C. Tan, M. Monne-van Muijen, F. Koning, A. M. Kruisbeek, and G. M. van Bleek. 1996. Isolation of an immunodominant viral peptide that is endogenously bound to the stress protein HSP96/GRP94. Proc. Natl. Acad. Sci. USA 93:6135.
11. Ishii, T., H. Udono, T. Yamano, H. Ohta, A. Uenaka, T. Ono, A. Hizuta, N. Tanaka, P. K. Srivastava, and E. Nakayama. 1999. Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and hsp96. J. Immunol. 162:1303.
12. Breloer, M., T. Marti, B. Fleischer, and A. von Bonin. 1998. Isolation of processed, H-2Kb-binding ovalbumin-derived peptides associated with the stress proteins HSP70 and HSP96. Eur. J. Immunol. 28:1016.
13. Meng, S. D., T. Gao, G. F. Gao, and P. Tien. 2001. HBV-specific peptide associated with heat-shock protein HSP96. Lancet 357:528.
14. Arnold, D., S. Faath, H. Rammensee, and H. Schild. 1995. Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96. J. Exp. Med. 182:885.
15. Yamazaki, K., T. Nguyen, and E. R. Podack. 1999. Cutting edge: tumor secreted heat shock-fusion protein elicits CD8 cells for rejection. J. Immunol. 163:5178.
16. Castelli, C., A. M. Ciupitu, F. Rini, L. Rivoltini, A. Mazzocchi, R. Kiessling, and G. Parmiani. 2001. Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells. Cancer Res. 61:222.
17. Janetzki, S., D. Palla, V. Rosenhauer, H. Lochs, J. J. Lewis, and P. K. Srivastava. 2000. Immunization of cancer patients with autologous cancer-derived heat shock protein HSP96 preparations: a pilot study. Int. J. Cancer 88:232.
18. Belli, F., A. Testori, L. Rivoltini, M. Maio, G. Andreola, M. R. Sertoli, G. Gallino, A. Piris, A. Cattelan, I. Lazzari, et al. 2002. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunological findings. J. Clin. Oncol. 20:4169.
19. Mazzaferro, V., J. Coppa, M. G. Carrabba, L. Rivoltini, M. Schiavo, E. Regalia, L. Mariani, T. Camerini, A. Marchianò, S. Andreola, et al. 2003. Vaccination with autologous tumor derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin. Cancer Res. In press.
20. Kawakami, Y., S. Eliyahu, K. Sakaguchi, P. F. Robbins, L. Rivoltini, J. R. Yannelli, E. Appella, and S. A. Rosenberg. 1994. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180:347.
21. Rivoltini, L., Y. Kawakami, K. Sakaguchi, S. Southwood, A. Sette, P. F. Robbins, F. M. Marincola, M. L. Salgaller, J. R. Yannelli, E. Appella, and S. A. Rosenberg. 1995. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J. Immunol. 154:2257.
22. Nagorsen, D., U. Keilholz, L. Rivoltini, A. Schmittel, A. Letsch, A. M. Asemissen, G. Berger, H. J. Buhr, E. Thiel, and C. Scheibenbogen. 2000. Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer. Cancer Res. 60:4850.
23. Srivastava, P. K., and N. S. Jaikaria. 2001. Methods of purification of heat-shock protein-peptide complexes for use as vaccines against cancers and infectious diseases. Methods Mol. Biol. 156:175.
24. Champagne, P., G. S. Ogg, A. S. King, C. Knabenhans, K. Ellefsen, M. Nobile, V. Appay, G. P. Rizzardi, S. Fleury, M. Lipp, et al. 2001. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 410:106.
25. - effector subset exerting ex vivo tumor-specific cytolytic activity. Cancer Res. 62:1743.
26. Fong, L., Y. Hou, A. Rivas, C. Benike, A. Yuen, G. A. Fisher, M. M. Davis, and E. G. Engleman. 2001. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl. Acad. Sci. USA 98:8809.
27. Zwaveling, S., S. C. Ferreira Mota, J. Nouta, M. Johnson, G. B. Lipford, R. Offringa, S. H. van der Burg, and C. J. Melief. 2002. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J. Immunol. 169:350.
28. Carbone, F. R., C. Kurts, S. Bennett, J. F. Miller, and W. R. Heath. 1998. Cross-presentation: a general mechanism for CTL immunity and tolerance. Immunol. Today 8:368.
29. Strome, S. E., S. Voss, R. Wilcox, T. L. Wakefield, K. Tamada, D. Flies, A. Chapoval, J. Lu, J. L. Kasperbauer, D. Padley, et al. 2002. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response. Cancer Res. 62:1884.
30. Sombroek, C. C., A. G. Stam, A. J. Masterson, S. M. Lougheed, M. J. Schakel, C. J. Meijer, H. M. Pinedo, A. J. van den Eertwegh, R. J. Scheper, and T. D. de Gruijl. 2002. Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J. Immunol. 168:4333.
31. Pietra, G., R. Mortarini, G. Parmiani, and A. Anichini. 2001. Phases of apoptosis of melanoma cells, but not of normal melanocytes, differently affect maturation of myeloid dendritic cells. Cancer Res. 61:8218.
32. Castelli, C., A. Mazzocchi, F. Rini, P. Tarsini, L. Rivoltini, M. Maio, G. Gallino, F. Belli, and G. Parmiani. 1998. Immunogenicity of the ALLAVGATK (gp100[17-25]) peptide in HLA-A3.1 melanoma patients. Eur. J. Immunol. 28:1143.